Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients?

@article{DelPup2013PromestrieneAS,
  title={Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients?},
  author={Lino Del Pup and Raffaele Di Francia and Carla Cavaliere and Gaetano Facchini and Giorgio Giorda and Paolo De Paoli and Massimiliano Berretta},
  journal={Anti-Cancer Drugs},
  year={2013},
  volume={24},
  pages={989–998}
}
Urogenital symptoms resulting from estrogen deficiency are common problems that impair quality of life and sexuality. Potentially, one out of three postmenopausal women could benefit from a vaginal estrogen therapy, but the fear of systemic absorption limits its use. Promestriene used vaginally to relieve vaginal atrophy is a locally effective estrogen that has not shown systemic estrogenic effects. Thus, it could be a first-line option for those who necessitate a minimal or ideally no vaginal… 

Ospemifene: a safe treatment of vaginal atrophy

Ospemifene relieves moderate to severe symptoms of vulvovaginal atrophy, like dryness, irritation and soreness around the genital area, and painful sexual intercourse, in menopausal women, and it has neutral effects on endometrium and coagulation.

Pharmacotherapy for the treatment of vaginal atrophy

The authors provide an overview of the current pharmaceutical treatment for vulvovaginal atrophy, using a microscope to study the maturity index of the vaginal fluid, and provide their expert opinions on its future treatment.

Combination Local Therapy of Genitourinary Menopausal Syndrome Symptoms

Local combination hormone therapy with probiotic support can be an effective treatment option for genitourinary syndrome of menopause since it helps to enhance proliferative processes, improve blood circulation, restore biocenosis and relieve symptoms of coital pain.

Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial

In postmenopausal women with severe POP who underwent transvaginal PRS with mesh, non-VE therapy before surgery was noninferior to VE therapy regarding mesh exposure rate within 1 year of follow-up.

Management of genitourinary syndrome of menopause in breast cancer survivors: An update

The present data suggest that these therapies are effective for VVA in BCSs; however, safety remains controversial and a there is a major concern with all of these treatments.

Menopausal Hormone Therapy to Prevent Chronic Conditions

Findings from randomized clinical trials, as well as preclinical, clinical, and epidemiologic studies, clarify the favorable benefit-risk profile for MHT use by recently menopausal women with bothersome vasomotor and related menopausal symptoms.

Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels

  • R. Santen
  • Medicine, Biology
    Climacteric : the journal of the International Menopause Society
  • 2015
Low-dose vaginal estrogen appears to be an effective strategy for managing women whose symptoms result from vulvovaginal atrophy and low-doses regimens should be preferred clinically to intermediate- or high-dose methods.

Genitourinary Syndrome of Menopause.

  • J. Shifren
  • Medicine
    Clinical obstetrics and gynecology
  • 2018
Genitourinary syndrome of menopause (GSM) describes a collection of exam findings and bothersome symptoms associated with estrogen deficiency involving changes to the labia, introitus, clitoris,

Joint recommendations for the diagnosis and treatment of vulvo-vaginal atrophy in women in the peri- and post-menopausal phases from the Società Italiana per la Menopausa (SIM) and the Società Italiana della Terza Età (SIGiTE).

Herein, joint recommendations for diagnosis and treatment of vulvo-vaginal atrophy (VVA) in women in the peri- and post-menopausal phases from the Società Italiana per la Menopausa (SIM) and the

Vaginal estrogen and mammogram results: case series and review of literature on treatment of genitourinary syndrome of menopause (GSM) in breast cancer survivors

Low-dose vaginal estrogen use for 1 or more years in a small cohort of women with GSM did not appear to be associated with any changes in breast density or Bi-RADS breast cancer risk scores in the majority of study participants, including three breast cancer survivors.

References

SHOWING 1-10 OF 89 REFERENCES

Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview

The role, safety and effectiveness of topical vaginal estrogen therapy are provided, which reverse atrophic changes and relieve associated symptoms, while avoiding systemic effects.

Recommendations for the management of postmenopausal vaginal atrophy

  • D. SturdeeN. Panay
  • Medicine
    Climacteric : the journal of the International Menopause Society
  • 2010
These guidelines and recommendations are hoped that they will help to highlight this major cause of distress and reduced quality of life and will encourage women and their medical advisers all over the world to seek and provide help.

Urogenital disorders associated with oestrogen deficiency: the role of promestriene as topical oestrogen therapy

  • Isabel SantosS. Clissold
  • Medicine
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2010
Promestriene is an analogue of oestradiol which is minimally absorbed and it has been shown to be effective in reversing atrophic changes caused by oestrogen deficiency in women undergoing natural or surgically induced menopause.

[Safety of promestriene capsule used in postmenopausal atrophic vaginitis].

The premestriene capsule was safe and effective in the treatment of postmenopausal atrophic vaginitis and it was uncertain whether those events were associated with promestrienes use.

Presurgical promestriene therapy in postmenopausal women with stress urinary incontinence

The results of this study confirm the efficacy of remedial surgical treatment of SUI with TVT, and seem to favor trophism and vascularization of the whole muscular and fascial support of the pelvic floor and facilitates performance of the operation, but is not supported statistically.

Management of vaginal dryness and dyspareunia in estrogen sensitive cancer patients.

  • L. Del Pup
  • Medicine
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2012
Cancer patients suffer from vaginal dryness and dyspareunia earlier and longer than the general population, with more severe and distressing symptoms, and use of vaginal estrogens is particularly difficult in estrogen sensitive cancer patients because of their systemic absorption.

Dyspareunia in postmenopausal women: a critical review.

Empirical evidence suggests that dyspareunia is common in postmenopausal women, and that it is not highly correlated with menopausal status, estrogen levels or vaginal atrophy, and a change in perspective toward a multiaxial pain-focused approach is proposed for future research concerning dysPareunia in post menopausal women.

Should urogenital atrophy in breast cancer survivors be treated with topical estrogens?

The urogenital consequences of estrogen deprivation therapy in breast cancer patients is focused on and a simple guide of current and future strategies for managing these symptoms is provided.
...